My Top Pick for speculators for the coming year is a biotech company, explains leading growth and income stock specialist Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Vertex Pharmaceuticals (VRTX) is prominent for its world-leading treatments for cystic fibrosis. Vertex is expected to outperform its peers in earnings growth through 2020.
Vertex is expected to report earnings per share of $2.27 in 2017 (December year-end), reflecting 195% earnings growth. This aggressive growth stock has a 2017 price/earnings ratio of 34.
As you know, pharmaceutical stocks got....More>>>